Pfizer is collaborating with the German Breast Group to supervise PENELOPE-B, a phase III trial of palbociclib in patients with ER-positive, HER2-normal, high-risk, early-stage breast cancer who still have residual disease after being treated with neoadjuvant chemotherapy and surgery [37]. The gene discussed is ESR1; the disease is breast carcinoma.